
Company valuation, historical trends, and peer comparisons.
According to Spyre Therapeutics, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 9.06B. This represents a change of 69.40% compared to the average of 5.35B of the last 4 quarters.
The mean historical Enterprise Value of Spyre Therapeutics, Inc. over the last ten years is 405.02M. The current 9.06B Enterprise Value has changed 2.14% with respect to the historical average. Over the past ten years (40 quarters), SYRE's Enterprise Value was at its highest in in the September 2026 quarter at 7.79B. The Enterprise Value was at its lowest in in the June 2023 quarter at -187908015.60.
Average
405.02M
Median
181.70M
Minimum
-40468161.20
Maximum
2.01B
Discovering the peaks and valleys of Spyre Therapeutics, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 100.20%
Maximum Annual Enterprise Value = 2.01B
Minimum Annual Increase = -2584.37%
Minimum Annual Enterprise Value = -40468161.20
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 2.01B | 100.20% |
| 2024 | 1.01B | -2584.37% |
| 2023 | -40468161.20 | -626.08% |
| 2022 | 7.69M | -97.45% |
| 2021 | 302.20M | -9.89% |
| 2020 | 335.39M | 45.88% |
| 2019 | 229.91M | 72.21% |
| 2018 | 133.50M | 93.40% |
| 2017 | 69.03M | -1439.28% |
| 2016 | -5153996.25 | -106.26% |
The current Enterprise Value of Spyre Therapeutics, Inc. (SYRE) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
992.56M
5-year avg
657.52M
10-year avg
405.02M
Spyre Therapeutics, Inc.’s Enterprise Value is greater than Odyssey Therapeutics, Inc. (879.98M), greater than AnaptysBio, Inc. (1.56B), greater than Immunic, Inc. (-46193940.00), greater than Abivax S.A. (6.58B), greater than Aclaris Therapeutics, Inc. (522.52M), greater than AgomAb Therapeutics N.V. American Depositary Shares (79.32M), greater than InflaRx N.V. (113.27M), greater than Upstream Bio, Inc. (124.21M), greater than Ardelyx, Inc. (1.03B),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 879.98M | $937.14M | |
| 1.56B | $1.42B | |
| -46193940.00 | $108.34M | |
| 6.58B | $7.51B | |
| 522.52M | $541.69M | |
| 79.32M | $337.35M | |
| 113.27M | $218.10M | |
| 124.21M | $202.65M | |
| 1.03B | $819.83M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Spyre Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Spyre Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Spyre Therapeutics, Inc.'s Enterprise Value?
What is the highest Enterprise Value for Spyre Therapeutics, Inc. (SYRE)?
What is the 3-year average Enterprise Value for Spyre Therapeutics, Inc. (SYRE)?
What is the 5-year average Enterprise Value for Spyre Therapeutics, Inc. (SYRE)?
How does the current Enterprise Value for Spyre Therapeutics, Inc. (SYRE) compare to its historical average?